ReviewExpert review of hematology2019
Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.
Review in Expert review of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Machine learning enhances risk stratification and treatment failure prediction in diffuse large B-cell lymphoma.HemaSphere · 2026Article
- Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients.Annals of hematology · 2026Article
- Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Clinical applications of artificial intelligence in the histopathology of lymphoma: diagnosis, treatment and prognosis.Discover oncology · 2025Review
- Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma.BJC reports · 2025Article
- Mechanism of Action of circRNA/miRNA Network in DLBCL.Non-coding RNA · 2025Review
- EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.Frontiers in immunology · 2025Review
- Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study - development of a clinical nomogram.Annals of hematology · 2025Article
- Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.Cancer medicine · 2024Article
- Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.Leukemia & lymphoma · 2024Review
- Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models.Blood cancer journal · 2023Article
- Iterated cross validation method for prediction of survival in diffuse large B-cell lymphoma for small size dataset.Scientific reports · 2023Article
- Sequencing therapy in relapsed DLBCL.Hematology. American Society of Hematology. Education Program · 2022Article
- Predictive models for clinical decision making: Deep dives in practical machine learning.Journal of internal medicine · 2022Review
- A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects.Journal of medical Internet research · 2022Review
- Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.Inflammation · 2022Article
- Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma.Journal of Cancer · 2022Article
- Data-driven support to decision-making in molecular tumour boards for lymphoma: A design science approach.Frontiers in oncology · 2022Article
- Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.Quantitative imaging in medicine and surgery · 2021Article
- Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models - A Systematic Review.Clinical epidemiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.